Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you order an OncoType DX test on a <50 year old woman with T2 N1mi HR+ HER2- breast cancer?
Answer from: Medical Oncologist at Community Practice
Yes. The patient will need chemotherapy as per RxPonder Trial.
Comments
Medical Oncologist at Hollywood Private Hospital
Is this correct? The protocol of RxPonder states-&...
Medical Oncologist at Los Angeles VA Medical Center
For micrometastases and how to interpret, please s...
7816
7819
Sign in or Register to read more
11847
Related Questions
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
In light of WSG-ADAPT HR+/HER2– trial showing a benefit at SABCS 2024 with neoadjuvant nab-paclitaxel over paclitaxel in patients with HR-positive, HER2-negative, terms of 5 year IDFS, does it change your practice?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Is this correct? The protocol of RxPonder states-&...
For micrometastases and how to interpret, please s...